Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study
Language English Country Switzerland Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Down-Regulation genetics MeSH
- Exosomes genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- MicroRNAs genetics urine MeSH
- Biomarkers, Tumor genetics urine MeSH
- Endometrial Neoplasms diagnosis genetics urine MeSH
- Ovarian Neoplasms diagnosis genetics urine MeSH
- Pilot Projects MeSH
- Prognosis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Up-Regulation genetics MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- MicroRNAs MeSH
- Biomarkers, Tumor MeSH
Among gynaecological cancers, epithelial ovarian cancers are the most deadly cancers while endometrial cancers are the most common diseases. Efforts to establish relevant novel diagnostic, screening and prognostic markers are aimed to help reduce the high level of mortality, chemoresistance and recurrence, particularly in ovarian cancer. MicroRNAs, the class of post-transcriptional regulators, have emerged as the promising diagnostic and prognostic markers associated with various diseased states recently. Urine has been shown as the source of microRNAs several years ago; however, there has been lack of information on urine microRNA expression in ovarian and endometrial cancers till now. In this pilot study, we examined the expression of candidate cell-free urine microRNAs in ovarian cancer and endometrial cancer patients using quantitative real-time PCR. We compared the expression between pre- and post-surgery ovarian cancer samples, and between patients with ovarian and endometrial cancers and healthy controls, within three types of experiments. These experiments evaluated three different isolation methods of urine RNA, representing two supernatant and one exosome fractions of extracellular microRNA. In ovarian cancer, we found miR-92a significantly up-regulated, and miR-106b significantly down-regulated in comparison with control samples. In endometrial cancer, only miR-106b was found down-regulated significantly compared to control samples. Using exosome RNA, no significant de-regulations in microRNAs expression could be found in either of the cancers investigated. We propose that more research should now focus on confirming the diagnostic potential of urine microRNAs in gynaecological cancers using more clinical samples and large-scale expression profiling methods.
See more in PubMed
Oncol Rep. 2011 Oct;26(4):995-1002 PubMed
PLoS One. 2009;4(4):e5311 PubMed
Cancer Sci. 2014 Jan;105(1):18-25 PubMed
BMC Cancer. 2012 Dec 28;12:627 PubMed
J Cancer. 2014 Jan 29;5(3):182-91 PubMed
Cancer Sci. 2010 Jan;101(1):241-9 PubMed
Cancer Sci. 2011 Mar;102(3):522-9 PubMed
Urol Oncol. 2010 Nov-Dec;28(6):655-61 PubMed
Neoplasma. 2011;58(6):457-68 PubMed
Br J Cancer. 2012 Feb 14;106(4):768-74 PubMed
BMC Bioinformatics. 2008 Jul 30;9:326 PubMed
Exp Hematol Oncol. 2014 May 20;3:14 PubMed
EMBO Mol Med. 2012 Mar;4(3):143-59 PubMed
Biotechnol Lett. 2004 Mar;26(6):509-15 PubMed
Gynecol Oncol. 2009 Jan;112(1):55-9 PubMed
Br J Cancer. 2014 Feb 18;110(4):976-83 PubMed
Clin Genitourin Cancer. 2012 Jun;10 (2):106-13 PubMed
Clin Chem. 2010 Nov;56(11):1733-41 PubMed
PLoS One. 2008 Jun 18;3(6):e2436 PubMed
Int J Cancer. 2013 Dec 1;133(11):2631-41 PubMed
Mol Cancer. 2008 Apr 28;7:35 PubMed
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 PubMed
Cancer Res. 2004 Aug 1;64(15):5245-50 PubMed
Mol Carcinog. 2014 May;53(5):349-59 PubMed
J Comput Biol. 2005 Oct;12(8):1047-64 PubMed
Br J Cancer. 2010 Aug 24;103(5):693-700 PubMed
Int J Mol Sci. 2013 Jun 06;14(6):12123-37 PubMed
